Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase.

Human mesenchymal stem cells (MSC) strongly repress activated T-cell proliferation through the production of a complex set of soluble factors, including the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO), which is induced by IFN-gamma. Conversely, MSCs support survival of follicular lymphoma (FL) B cells, in particular after exposure to tumor necrosis factor-alpha (TNF) and lymphotoxin-alpha1beta2 (LT). The role of MSCs on normal and malignant B-cell growth in steady-state and inflammatory conditions remains to be fully explored. We show here that resting MSCs sustain activated normal B-cell proliferation and survival, whereas IFN-gamma-conditioned MSCs mediate IDO-dependent B-cell growth arrest and apoptosis. IFN-gamma, TNF, and LT are significantly overexpressed by the microenvironment of invaded FL-lymph nodes, but their relative expression patterns are highly heterogeneous between samples. In vitro, IFN-gamma abrogates the B-cell supportive phenotype induced by TNF and LT on MSCs. Moreover, IFN-gamma overrules the growth promoting effect of MSCs on primary purified FL B cells. Altogether, these results underline the crucial role of the cytokine context in the local crosstalk between malignant cells and their microenvironment and provide new insights into our knowledge of the FL cell niche that emerges as a new promising target for innovative therapeutic strategies.

[1]  Chen Wen-min.  Immunoregulatory Function of Mesenchymal Stem Cells , 2009 .

[2]  S. Setty,et al.  IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease , 2008, European journal of immunology.

[3]  J. Mesirov,et al.  Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. , 2008, Cancer research.

[4]  M. Andreeff,et al.  Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells , 2008, Gene Therapy.

[5]  J. Radford,et al.  Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. , 2008, Blood.

[6]  H. Rammensee,et al.  Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. , 2008, Blood.

[7]  A. Martini,et al.  Bone Marrow‐Derived Mesenchymal Stem Cells Induce Both Polyclonal Expansion and Differentiation of B Cells Isolated from Healthy Donors and Systemic Lupus Erythematosus Patients , 2008, Stem cells.

[8]  N. Rouas-Freiss,et al.  Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.

[9]  D. von Bubnoff,et al.  Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? , 2007, The American journal of pathology.

[10]  W. Zimmermann,et al.  Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[11]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[12]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[13]  A. Cope,et al.  The Antiproliferative Effect of Mesenchymal Stem Cells Is a Fundamental Property Shared by All Stromal Cells1 , 2007, The Journal of Immunology.

[14]  J. Ryan,et al.  Interferon‐γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells , 2007 .

[15]  M. Haniffa,et al.  Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells1 , 2007, The Journal of Immunology.

[16]  Monika Engelhardt,et al.  Essential role of stromally induced hedgehog signaling in B-cell malignancies , 2007, Nature Medicine.

[17]  G. Prendergast,et al.  Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.

[18]  J. Tao,et al.  Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-κB (RelB/p52) in non-Hodgkin's lymphoma cells , 2007, Leukemia.

[19]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[20]  O. Ringdén,et al.  Mesenchymal Stem Cells Stimulate Antibody Secretion in Human B Cells , 2007, Scandinavian journal of immunology.

[21]  E. Lam,et al.  Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth , 2007, Leukemia.

[22]  K. Tarte,et al.  Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. , 2007, Blood.

[23]  B. Sander,et al.  CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma , 2007, Clinical Cancer Research.

[24]  J. Ryan,et al.  Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. , 2007, Clinical and experimental immunology.

[25]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Ronald N Germain,et al.  Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. , 2006, Immunity.

[27]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[28]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[29]  F. Benvenuto,et al.  Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.

[30]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[31]  F. Djouad,et al.  Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. , 2005, Arthritis and rheumatism.

[32]  A. Hagenbeek,et al.  Meta-analysis to evaluate the role of interferon in follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[34]  T. Kipps,et al.  Fibroblast-Like Synoviocytes of Mesenchymal Origin Express Functional B Cell-Activating Factor of the TNF Family in Response to Proinflammatory Cytokines1 , 2005, The Journal of Immunology.

[35]  G. Pizzolo,et al.  Role for IFN-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells , 2005 .

[36]  F. Marini,et al.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. , 2005, Cytotherapy.

[37]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[38]  H. Link,et al.  Interferon‐γ‐modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis , 2004 .

[39]  R. Dummer,et al.  Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. , 2004, Blood.

[40]  L. Xerri,et al.  Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d‘Etude des Lymphomes Folliculaires , 2004, British journal of haematology.

[41]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[42]  F. Djouad,et al.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.

[43]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[44]  L. Staudt,et al.  Decision making in the immune system: Lymphoid Malignancies: the dark side of B-cell differentiation , 2002, Nature Reviews Immunology.

[45]  Gerhard Opelz,et al.  Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic Cells , 2002, The Journal of experimental medicine.

[46]  G. Salles,et al.  Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas , 2000, Cancer Immunology, Immunotherapy.

[47]  J. Larsen,et al.  Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. , 2000, Blood.

[48]  T. Babcock,et al.  Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. , 2000, Cytokine.

[49]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[50]  E. Werner,et al.  Simultaneous measurement of serum tryptophan and kynurenine by HPLC. , 1997, Clinical chemistry.

[51]  R. Stahel,et al.  T‐cell derived cytokines co‐stimulate proliferation of CD40‐activated germinal centre as well as follicular lymphoma cells , 1997, Hematological oncology.

[52]  P. Gaulard,et al.  Interleukin-2 and interferon-gamma production in follicular lymphomas. , 1991, American journal of clinical pathology.